Should tumor depth be included in prognostication of soft tissue sarcoma? by Rydholm, Anders & Gustafson, Pelle
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Should tumor depth be included in prognostication of soft tissue 
sarcoma?
Anders Rydholm* and Pelle Gustafson
Address: Department of Orthopedics, University Hospital, SE-221 85 Lund, Sweden
Email: Anders Rydholm* - Anders.Rydholm@ort.lu.se; Pelle Gustafson - Pelle.Gustafson@ort.lu.se
* Corresponding author    
prognosissoft tissue sarcomastagingtumor depth
Abstract
Background: Most staging systems for soft tissue sarcoma are based on histologic malignancy-
grade, tumor size and tumor depth. These factors are generally dichotomized, size at 5 cm. We
believe it is unlikely that tumor depth per se should influence a tumor's metastatic capability.
Therefore we hypothesized that the unfavourable prognostic importance of depth could be
explained by the close association between size and depth, deep-seated tumors on average being
larger than the superficial ones. When tumor size is dichotomized, this effect should be most
pronounced in the large size (>5 cm) group in which the size span is larger.
Methods:  We analyzed the associations between tumor size and depth and the prognostic
importance of grade, size and depth in a population-based series of 490 adult patients with soft
tissue sarcoma of the extremity or trunk wall with complete, 4.5 years minimum, follow-up.
Results: Multivariate analysis showed no major prognostic effect of tumor depth when grade and
size were taken into account. The mean size of small tumors was the same whether superficial or
deep but the mean size of large and deep-seated tumors were one third larger than that of large
but superficial tumors. Tumor depth influenced the prognosis in the subset of high-grade and large
tumors. In this subset deep-seated tumors had poorer survival rate than superficial tumors, which
could be explained by the larger mean size of the deep-seated tumors.
Conclusion: Most of the prognostic value of tumor depth in soft tissue sarcomas of the extremity
or trunk wall can be explained by the association between tumor size and depth.
Background
Most staging systems for soft tissue sarcoma are based on
histologic malignancy grade, tumor size and tumor depth
(the French (FNCLCC) system [1]; the Memorial Sloan
Kettering (MSK) system [2]; the American Joint Commit-
tee on Cancer/International Union Against Cancer AJCC/
UICC system 5th ed [3]. However, we think it is unlikely
that tumor depth per se, all other things being equal,
should influence the risk of metastatic spread from a soft
tissue sarcoma. One explanation for the prognostic value
of tumor depth could be the association between depth
and tumor size, deep-seated tumors being larger. Most
systems dichotomize size at 5 cm. Prognostic information
from tumor depth may be obtained if each size group (1–
5/>5 cm) is divided into superficial and deep-seated
tumors if the mean size of the deep-seated tumors is larger
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than that of the superficial tumors. A prognostic effect of
tumor depth could then be related to size and should be
strongest in the large size group in which the size span is
greater. We tested this hypothesis in a large population-
based series of soft tissue sarcoma of the extremity and
trunk wall in adults.
Patients and methods
The southern Sweden soft tissue sarcoma database is pop-
ulation-based, i.e. all patients diagnosed with a soft tissue
sarcoma within a defined geographical region (currently
1.5 million inhabitants) are included, irrespective of
whether treated at our sarcoma center in Lund or at other
hospitals in the region. Patients not referred to our center
are identified via the Regional Tumor Registry. All patients
with malignant tumors are reported to this Registry by a
double-reporting system: every clinician and every pathol-
ogist who diagnoses a malignant tumor is obliged to
report to the registry. For patients not referred to out sar-
coma center, clinical data are obtained from the medical
records and archived tumor material is reviewed by our
center pathologists. The database includes all adult
patients with a soft tissue sarcoma in the extremity or
trunk wall. Strictly cutaneous sarcomas (most of them
small leiomyosarcomas of the skin which almost never
metastazise), dermatofibrosarcoma protuberans, syn-
drome-related sarcomas (e.g. sarcomas in patients with
neurofibromatosis) and radiation induced sarcomas are
not included. For a detailed description of the database,
see Gustafson [4].
During the 25-year period 1973–1997, 578 patients were
included. 44 patients who had metastases demonstrated
already at diagnosis of the primary tumor and 44 patients
who had had tumors that were not at least marginally
excised were excluded, which left 490 patients for this
study. 300 were referred to our tumor center before sur-
gery (half of them after needle biopsy), 127 immediately
after surgery (most often marginal excision of small and
superficial tumors), 21 first after local recurrence, and 42
patients were not referred at all. 90 patients were given
local radiotherapy (most often postoperatively) and 34
patients were given adjuvant chemotherapy for the pri-
mary tumor according to several regimens. These patients
were not separately analyzed; local radiotherapy influ-
ences mainly the local recurrence rate and the chemother-
apy used has no major effect on distant metastases.
The mean age at diagnosis was 62 (17–94) years. 52 % of
the patients were men. Nine tenths of the tumors were
located in the extremities, almost half of them in the thigh
and hip girdle. Two thirds (321/490) of the tumors were
deep-seated. The mean size was 8.3 cm for deep-seated
tumors and 5,2 cm for superficial tumors. Two thirds of
the tumors (325/490) were larger than 5 cm. Malignant
fibrous histiocytoma (219) was the commonest histotype
(most of these tumors were diagnosed in the 1980's) fol-
lowed by leiomyosarcoma (73), liposarcoma (54), syno-
vial sarcoma (38) and malignant peripheral nerve sheath
tumors (18). The tumors were malignancy-graded on a 4-
tiered scale with decreasing survival rates associated with
increasing grade. Most staging systems dichotomize grade
but the definition of low and high malignancy grade is not
clear-cut. Therefore, we used two alternative dichotomiza-
tions being: grades I and II versus grades III and IV and
grades I-III versus grade IV (Table 1).
Follow-up was complete for a minimum of 4.5 years or
until death. The median follow-up time for the survivors
was 11 (min 4.5, max 26) years. During the observation
period 151 patients developed metastatic disease, 122 of
these have died because of tumor. Local recurrence
occurred in 55/300 (18%) of patients referred before sur-
gery and in 64/190 (34%) patients referred after surgery or
not referred for the primary tumor.
Terminology and Statistics
Tumors superficial to the deep fascia are called superficial,
all others are called deep. Small tumors are 5 cm or less in
largest diameter, all other tumors are called large. High
grade refers to either grades III-IV tumors or grade IV
tumors as indicated in text. Survival was analyzed in terms
of metastasis-free survival; death and other metastasis-free
causes for ending follow-up were treated as censoring.
Presented rates indicate 5-year metastasis-free survival
and were calculated using the Kaplan-Meier method. Mul-
tiple prognostic factors were analyzed simultaneously
using Cox's proportional hazards model. The statistical
analyses were performed by Jonas Ranstam, PhD, CStat,
Lund, Sweden.
Abbreviations in the Tables: RR relative risk, CI confi-
dence interval.
Results
Size related to depth (Table 2)
In the small (1–5 cm) tumor group the mean tumor size
was similar for superficial and deep tumors. However, in
the large (>5 cm) tumor group the mean size of deep
tumors was one third larger than that of superficial
tumors. The findings were almost identical if only high
grade tumors (irrespective of the classification of high-
grade) were analyzed (data not shown).
Prognostic factors in total material (Table 3)
Multivariate analysis of size, depth, and grade (dichot-
omized in two ways) showed size and grade to be of inde-
pendent prognostic value, irrespective of definition of
high grade. When size and grade were taken into account,
depth had no major effect on survival, neither in the totalBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/17
Page 3 of 5
(page number not for citation purposes)
series nor when separately analyzed in MFH, leiomyosar-
coma, liposarcoma, synovial sarcoma, and the remaining
histotypes as one group (data not shown).
Prognosis related to combinations of depth, size and grade 
(Tables 4,5, Figure 1)
The survival rate for small and low (I-II or I-III) grade
tumors was similar whether the tumor was superficial or
deep. Likewise, the survival rate for small and high (III-IV
or IV) grade tumors was similar whether the tumor was
superficial or deep. However, for large and high grade
tumors the survival rate was lower for deep than superfi-
cial tumors. These observations were the same irrespective
of how grade was dichotomized.
Prognosis based on only grade and size (Tables 6,7)
After finding that depth had no major prognostic value we
assessed staging based on only grade (low, high (III-IV or
IV)) and size. We categorized size in 3 groups, 1–5 cm, 6–
10 cm, and larger than 10 cm. We found that a 4 tiered
staging system led to decreasing survival with increasing
stage with good separation of the survival rate between the
stages. We made the same observations irrespective of
how grade was dichotomized.
Discussion
Many staging systems for soft tissue sarcomas of the
extremity and trunk wall have been proposed but none is
generally accepted. One reason may be that it is
impossible to create a system common for all entities of
soft tissue sarcoma since prognostic factors vary regarding
Table 1: Survival according to histologic grade.
Grade(s) No. of patients Survival 95% CI
All 490 0.71 0.75–0.67
I2 7 1 . 0
II 67 0.97 1.0–0.93
III 124 0.79 0.87–0.72
IV 272 0.57 0.63–0.51
I-II 94 0.98 1.0–0.95
I-III 218 0.87 0.90–0.85
III-IV 396 0.64 0.69–0.59
Table 2: Mean size (cm) and depth (n = 490)
Size category 1–5 cm >5 cm
size range number size range number
Superficial 2.9 (1–5) 87 7.6 (6–28) 82
Deep 2.8 (1–5) 78 10.1 (6–30) 243
Table 3: Prognostic factors, multivariate analysis (n = 490)
High grade=III-IV High grade=IV
RR 95% CI RR 95% CI
Large size 2.4 1.5–3.7 2.6 1.7–4.0
Deep location 1.3 0.86–1.8 1.4 0.96–2.0
High grade 2.5 1.6–3.7 15 4.8–47
Figure 1
Venn diagram showing approximate 5-yr metastasis-free sur-
vival rates in the 8 combinations of depth, size and grade 
(high=III-IV). For exact survival rates see Table 4. Green 
fields include the four subsets of low grade tumors. The sur-
vival rates are between 1 and 0.9 irrespective of depth and 
size. Blue fields include the two subsets of small high grade 
tumors, both with survival rates of 0.8. Red fields include the 
two subsets of large and high grade tumors. The survival 
rates differ, being 0.7 for superficial tumors and 0,5 for deep 
tumors. The explanation is that the mean size of deep-
seated, large tumors is greater than that of superficial, large 
tumors, see Table 2. The principal findings are the same 
when high grade is defined as grade IV, see Table 5.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/17
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type and strength between histotypes [4]. Our aim with
this study was not to suggest a new staging system but to
analyze the rationale for using tumor depth as a prognos-
tic factor.
Histologic malignancy-grade and tumor size are undis-
puted strong prognostic factors in soft tissue sarcoma and
are consequently included in all staging systems, most of
which also include tumor depth. However, there is a well-
known association between tumor depth and size and
some authors have found similar survival in patients with
superficial and deep tumors when stratified according to
grade and size [5,6]. The largest prognostic study on soft
tissue sarcoma hitherto published, based on 2,136
patients treated at the Memorial Sloan-Kettering Cancer
Center, showed that both size and depth were of prognos-
tic importance [7]. That study included one fifth retroin-
traabdominal and visceral tumors which all by definition
are deep-seated and with a poor prognosis, sometimes
killing the patient because of uncontrollable local growth
despite being low grade without metastatic spread. This
may, at least in part, explain the independent prognostic
value of depth. Recently two other large studies on staging
of soft tissue sarcoma arrived at different conclusions:
Wunder et al [2] found that a system utilizing grade,
depth, and size (all factors dichotomized) would better
predict patient outcome and stratify risk than one using
only grade and size whereas Ramanathan et al [8] pro-
posed a staging system based on only grade and 4 groups
of size.
We find it less probable that whether a sarcoma arises and
grows in or outside the deep fascia investing the extremi-
ties and trunk wall should influence the metastatic proc-
ess – tumor growth into blood vessels with release of
tumor cells into the circulation followed by adherence
and growth of these tumor cells in their new environment.
One explanation for a prognostic importance of tumor
depth that we have explored could be that certain histo-
types are predominantly deep-seated and that these spe-
cific histotypes are more prone to metastasize even when
adjusted for size and grade. We could not find that this
was an explanation for the prognostic importance of
depth. Indeed the fraction of deep-seated tumors and the
prognostic strength of high malignancy-grade varied
between histotypes, however, leiomyosarcoma was the
histotype with the highest fraction superficial tumors
(even though skin leiomyosarcomas were not included)
but also the histotype that had the highest relative risk for
metastatic disease associated with high malignancy-grade
(data not shown). We therefore chose to closer analyze
the relation between size and depth of tumors.
Most staging systems dichotomize tumor size (largest
diameter) in 1–5 cm/>5 cm. The 5 cm designation some-
Table 4: Survival according to combinations of depth, size and 
grade. High grade = III-IV
Prognostic factor
Deep Large High grade n Survival 95% CI
00 0 1 8 1 . 0
+0 0 2 2 1 . 0
0 + 0 15 0.93 1.0–0.81
+ + 0 39 0.97 1.0–0.91
0 0 + 69 0.81 0.91–0.72
+ 0 + 56 0.81 0.92–0.70
0 + + 67 0.67 0.79–0.55
+ + + 204 0.53 0.60–0.46
Table 5: Survival according to different combinations of depth, 
size and grade. High grade = IV
Prognostic factor
Deep Large High grade n Survival 95% CI
0 0 0 48 0.94 1.0–0.87
+ 0 0 50 0.94 1.0–0.87
0 + 0 41 0.80 0.92–0.68
+ + 0 79 0.83 0.92–0.75
0 0 + 39 0.74 0.89–0.59
+ 0 + 28 0.74 0.91–0.58
0 + + 41 0.65 0.81–0.49
+ + + 164 0.48 0.56–0.40
Table 6: Staging by grade (high grades = III-IV) and tumor size 
trichotomized.
Grade Size (cm) No. of patients Survival 95% CI
I-II any 94 0.97 0.99–0.96
III-IV 1–5 125 0.81 0.88–0.74
III-IV 6–10 198 0.62 0.69–0.55
III-IV >10 73 0.42 0.54–0.30
Table 7: Staging by grade (high grade = IV) and tumor size 
trichotomized.
Grade Size (cm) No. of patients Survival 95% CI
I-III any 218 0.87 0.90–0.85
IV 1–5 95 0.70 0.80–0.61
IV 6–10 116 0.55 0.65–0.46
IV >10 61 0.41 0.54–0.28BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/17
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times seems arbitrarily chosen, perhaps based on praxis
rather than updated analyses. When different size thresh-
olds have been tested to distinguish patients with poor
and good prognosis, 6 cm [9], 8 cm [10] and 10 cm [4]
have been used. Probably each increase of size increases
the risk for metastatic spread. Trovik et al [11] found that
the relative risk for metastatic disease increased by 1.5 per
5 cm increment of tumor size. Suit et al [12] studied 6
groups of size and found an increasing risk of metastases
with increasing size. We made the same observation.
We also found that when size is dichotomized at 5 cm, the
mean size of small tumors (1–5 cm) is the same irrespec-
tive of whether the tumor is superficial or deep. However,
in the large tumor group (>5 cm) the size of deep tumors
were one third greater than that of superficial tumors. This
seems to explain the prognostic value of depth when size
is dichotomized at 5 cm. This prognostic effect of tumor
depth was evident only in large and high-grade tumors
where the deep-seated tumors had the poorest prognosis
(Figure). Although we observed the effect only in large
and high-grade tumors this subset comprises about one
half of all tumors (Tables 4,5,6,7). The reason that we
could not find any prognostic importance of tumor depth
in large but low-grade tumors is probably the good prog-
nosis for low-grade tumors.
Since we found tumor depth of no major prognostic value
we assessed prognostication based on only grade and size,
but with size divided into 3 groups (<5, 6–10, >10 cm)
and found that patients could be allocated to 4 groups, 1
with low grade tumors (either grades I-II or grades I-III)
with good survival irrespective of tumor size and 3 groups
of patients with high grade tumors and with increasing
size being associated with decreasing survival. This find-
ing is by no means new; see for example Ramanathan et al
[8] and references therein. We also found this staging
prognostically more discriminative than a system based
on the number of dichotomized risk factors – e.g. grade,
size and depth – present. For example, a tumor with two
risk factors is either a deep and large, a deep and high-
grade, or a large and high-grade tumor. In our patient
series the survival rates varied considerably between these
combinations, being highest for deep and large tumors
and lowest for for high-grade and large tumors (Tables
4,5,6,7)
In conclusion, we found no evidence of tumor depth
being a major prognostic factor for metastatic disease in
soft tissue sarcoma of the extremity and trunk wall. Only
when tumor size is dichotomized at 5 cm does depth
contribute prognostic information. We suggest it is con-
ceptually better to disregard depth and optimize the infor-
mation from size by using more than two size categories.
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